A2 Biotherapeutics develops Tmod™, a precision-targeting T cell therapy platform that distinguishes solid tumors from normal cells by exploiting specific gene losses unique to cancer cells. This approach addresses the challenge of effective treatment for solid tumors while minimizing damage to healthy tissue.

Abax Sensing develops advanced sensor technology for industrial monitoring and control applications. Their solutions provide high-accuracy data acquisition for harsh environments, enabling predictive maintenance and process optimization. The company specializes in robust, integrated sensing platforms for machinery and infrastructure health monitoring.

AIForceTech manufactures unmanned agricultural machinery that utilizes artificial intelligence for precision farming. This technology enhances crop yield and reduces labor costs by automating tasks such as planting, monitoring, and harvesting.

Akaso Bio develops high-performance microsphere products, including purification fillers and immunomagnetic beads, utilizing advanced microfluidic technology and modular design for precise control over particle size and material properties. Their solutions address the need for reliable and efficient core materials in biomedicine and in vitro diagnostics, facilitating streamlined research and development processes for global healthcare clients.

Align is a platform that centralizes customer conversations across various data sources, utilizing AI to automatically analyze feedback and identify trends, product gaps, and win/loss reasons. By providing instant, verified answers to sales teams, Align reduces response times and enhances the efficiency of customer interactions, saving over 10 hours per sales engineer each week.

Cellbri manufactures automated CGT industrial instruments designed for efficient cell processing in biomanufacturing. Their technology enhances the precision and scalability of cell therapies, addressing the need for reliable and consistent production methods in the growing biotech sector.

Chance Pharmaceuticals is a clinical-stage biotechnology company developing inhalation therapies for respiratory and central nervous system diseases using a proprietary virtual reality drug development platform. The company focuses on improving drug formulations and expanding the application of biologics in inhalation treatments to enhance patient quality of life.

Core Medical Technology develops ventricular assist devices that provide mechanical support for patients with severe heart failure. These devices enhance blood circulation, improving patient outcomes and quality of life for individuals awaiting heart transplants or managing chronic heart conditions.

Danwang Medical specializes in regenerative medicine and organoid technology, providing a comprehensive organoid biobank and custom model development for various cancers. Their solutions enable pharmaceutical companies to conduct precise drug screening and toxicology evaluations, addressing the need for more effective and personalized cancer treatments.

Dify is an open-source platform for developing applications that utilize large language models (LLMs), enabling users to create AI workflows and autonomous agents with integrated Backend as a Service (BaaS) capabilities. The platform addresses the complexity of orchestrating LLM applications by providing tools for visual design, data pipeline management, and enterprise-level model optimization.

FIT2CLOUD provides a Multi-Cloud Management Platform that enables Chinese digital teams to efficiently manage and secure their cloud infrastructure through open-source tools. The platform addresses the challenges of operational oversight and security compliance in multi-cloud environments, enhancing resource management and audit capabilities.

Hesguard develops and manufactures implantable medical devices specifically designed for the treatment of ophthalmic diseases. Their products aim to improve patient outcomes by providing targeted therapeutic solutions that address vision-related health issues.

HiFiBiO Therapeutics provides a Drug Intelligence Science (DIS®) platform that combines proprietary high‑fidelity single‑cell sequencing and phenotyping with AI/ML analytics to identify therapeutic targets, generate lead antibodies, and predict biomarkers for immunotherapies. The end‑to‑end workflow delivers over 10,000 cell profiles per assay and real‑time functional readouts, enabling pharmaceutical and biotech partners to accelerate candidate selection and IND filing.

HJIMI develops 3D computer vision and intelligent human-machine interaction technologies to enhance user experiences in augmented reality (AR) and mixed reality (MR) applications. The company focuses on improving spatial awareness and interaction accuracy, enabling more intuitive and effective user engagement in digital environments.

Hong Jing Drive offers a full-stack computing platform for autonomous vehicles, integrating sensor selection, system calibration, and software development to enhance vehicle automation. The platform addresses the need for efficient and safe transportation by enabling the deployment of reliable autonomous driving systems.

Hummingbird Bioscience develops next-generation antibody-drug conjugates (ADCs) using proprietary linker-payload technologies to target cancer cells with high specificity. Their approach aims to provide effective treatment options for patients who do not respond to existing therapies, enhancing the potential for durable clinical responses.

IAN Intelligent Agent Network utilizes a decentralized Layer 2 infrastructure to integrate multiple AI agents, providing unbiased insights and enhancing trust through its Trust Engine, which scores Focus and Consistency. This approach addresses the issues of disinformation and bias in AI models, ensuring secure and transparent decision-making for businesses and individuals.

iCamuno Biotherapeutics develops a cell therapy drug using induced pluripotent stem cells (iPSCs) and gene editing technologies to create effective and affordable treatments for cancer patients. The company focuses on somatic cell reprogramming and stem cell differentiation to provide universal access to safe cellular therapies that meet unmet clinical needs.

iGent AI develops Maestro, an intelligent agent that integrates multiple AI models to enhance the software development process by autonomously generating, testing, and refining code in real-time. This platform addresses the challenges of managing complex codebases and accelerates development while reducing errors through adaptive learning and secure execution environments.

Immunofoco develops CAR-T cell therapies that treat solid tumors as hematologic malignancies, utilizing platforms like Peri Cruiser® and SNR to enhance tumor infiltration and reduce toxicity. Their approach addresses the challenge of tumor metastasis and recurrence by effectively targeting circulating tumor cells and microlesions, aiming to improve long-term survival rates for patients.

Joinband provides a cloud‑based incentive management platform that lets finance teams create, track, and analyze rebates, SPAs, co‑op funds, promotions, and sponsorships in one place. The solution uses AI to extract and validate invoice data, automates workflow approvals, and delivers real‑time analytics with program rankings and opportunity insights, while integrating with major ERP and CRM systems via pre‑built connectors or open APIs.

Juventas develops immune cell therapeutic drugs that utilize advanced cell engineering techniques to enhance the body's natural immune response against cancer and autoimmune diseases. The company targets the limitations of traditional therapies by providing more effective treatment options that improve patient outcomes and reduce side effects.

Lemon Photonics manufactures high-performance laser chips, including VCSEL, HCSEL, and edge-emitting lasers, designed for applications in 3D sensing, industrial processing, and medical aesthetics. The company addresses the need for reliable, high-quality laser solutions by ensuring a monthly production capacity of over 4,000 six-inch wafers, supported by a robust supply chain and quality assurance system.

Lü offers an interactive audiovisual system that turns any wall in a gym, classroom, or community hall into a high‑definition, touch‑responsive canvas for active learning. Combining ceiling‑mounted projectors, motion‑sensing cameras, lighting, and spatial audio, the platform delivers 45+ curriculum‑aligned apps and customizable content for 5‑12‑year‑olds, supporting 25‑50+ children simultaneously. Schools and recreation centers can purchase the hardware outright and add a Lü+ subscription for premium apps and ongoing content updates.